sorafenib has been researched along with parthenolide in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (parthenolide) | Trials (parthenolide) | Recent Studies (post-2010) (parthenolide) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 612 | 5 | 323 |
| Protein | Taxonomy | sorafenib (IC50) | parthenolide (IC50) |
|---|---|---|---|
| Nitric oxide synthase, inducible | Mus musculus (house mouse) | 4.525 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, S; Liang, P; Lv, H; Wu, H; Zhang, Z | 1 |
1 other study(ies) available for sorafenib and parthenolide
| Article | Year |
|---|---|
Preparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Compounding; Drug Liberation; Drug Stability; Drug Synergism; Female; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Sesquiterpenes; Solubility; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |